Catalyst Event
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (6990) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
6/2/2026, 12:00:00 AM
Kelun-Biotech announced positive first-in-human study results for its novel B7-H3 ADC drug, SKB500, at the 2026 ASCO annual meeting on June 2, 2026. The data showed broad-spectrum antitumor activity across multiple solid tumors, with notable efficacy in small cell lung cancer (SCLC).
Korean Translation
2026년 6월 2일 ASCO 연례회의에서 신규 B7-H3 ADC 약물 SKB500의 첫 인체 대상 임상 연구에서 긍정적인 결과를 발표함. 데이터는 다양한 고형암에 걸쳐 광범위한 항종양 활성을 보였으며, 특히 소세포폐암(SCLC)에서 주목할 만한 효능을 나타냄.
Related Recent Events
Ambu A/S (AMBUB) · Earnings Release
Q3 2025/26 earnings release scheduled. (Low importance estimated for a routine scheduled event).
8/26/2026, 12:00:00 AM
Boston Scientific Corp (BSX) · Earnings Release
Q2 2026 earnings results and conference call for July 29, 2026, before market open scheduled
7/29/2026, 12:00:00 AM
Integer Holdings Corp (ITGR) · Earnings Release
Analysts forecast the next quarterly earnings release for 2026-07-23 estimated. Estimated Medium importance as earnings reports typically drive significant price volatility.
7/23/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet Q2 2026 earnings release scheduled for July 22, 2026, with analysts forecasting EPS of approximately $2.85-$2.87 forecasted.
7/22/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
7/16/2026, 12:00:00 AM
Pharmaron Beijing Co Ltd (3759) · Other
The ex-dividend date for the RMB 0.20 per share final dividend on July 7, 2026, with payment on August 7, 2026; market reaction is estimated at Low as the payout is within expected ranges scheduled.
7/7/2026, 12:00:00 AM